Clinical trialNCT07284758RecruitingPhase 2Interventional

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

SponsorC4 Therapeutics, Inc.Enrollment100Multiple MyelomaRelapsed/Refractory Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Aurore Perrot, M.D.
Universite de Toulouse
Principal Investigator
clinicaltrials.gov ↗
Binod Dhakal, M.D.
Medical College of Wisconsin
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Martin Kaiser, M.D.
The Royal Marsden
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom

Imperial College Healthcare Nhs Foundation Trust - Hammersmith Hospital
London, United Kingdom, United Kingdom
Recruiting

United States

Clearview Cancer Institute
Huntsville, Alabama, United States
Recruiting
Mayo Clinic - Arizona
Phoenix, Arizona, United States
Recruiting
Honorhealth
Scottsdale, Arizona, United States
Recruiting
Berenson Cancer Center
West Hollywood, California, United States
Recruiting
Mayo Clinic - Florida
Jacksonville, Florida, United States
Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Recruiting
Indiana University Health
Indianapolis, Indiana, United States
Recruiting
University of Iowa
Iowa City, Iowa, United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Start Midwest
Grand Rapids, Michigan, United States
Recruiting
Mayo Clinic - Minnesota
Rochester, Minnesota, United States
Recruiting
Washington University/siteman Cancer Center
St Louis, Missouri, United States
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
the Tisch Cancer Institute/mount Sinai
New York, New York, United States
Recruiting
Unc Hospitals Adult Oncology Clinics
Chapel Hill, North Carolina, United States
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Recruiting
Start San Antonio
San Antonio, Texas, United States
Recruiting
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, United States
Recruiting
Mcw-Clinical Cancer Center at Froedtert Hospital Campus
Milwaukee, Wisconsin, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CemsidomideDexamethasone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Feb 2026
Primary completion: 31 Mar 2030
Completion: 31 Mar 2030
Last update posted: 6 Aug 2026
Registered enrollment: 100
Registry id: NCT07284758

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.